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Abstract 
 
Despite significant advances in our understanding of the molecular pathology 
of bladder cancer, it remains a significant health problem with high morbidity 
and mortality associated with muscle-invasive bladder cancer (stages T2+), 
and high costs associated with the surveillance of non-muscle-invasive 
bladder cancer (NMIBC, stages Ta/T1/Tis). Moreover, current diagnostic 
biomarkers are suboptimal and of poor utility for low grade disease and 
surveillance.  In this study we show that the Engrailed-2 (EN2) transcription 
factor is expressed in, and secreted by, bladder cancer cell lines and patient 
tumor specimens, justifying an evaluation of urinary EN2 as a diagnostic 
biomarker in bladder cancer using archived samples from an established 
biospecimen collection. In patients with NMIBC, urinary EN2 was detected in 
most cases with an overall sensitivity of 82% and specificity of 75%. The 
sensitivity for stage Ta and T1 tumors was 71% and 76%, respectively, and 
94% for stage T2+ tumors. This compares favorably with existing markers. 
The sensitivity for tumor grades 1, 2, and 3 was 69%, 78% and 87% 
respectively.  Thus urinary EN2 has the potential to be a more sensitive and 
specific protein biomarker for NMIBC than currently available tests. 
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Introduction 
 
Urothelial carcinoma of the urinary bladder (UCB) is the fourth and ninth most 
common cancer amongst men and women, respectively, in Europe and North 
America, with an estimated prevalence of 500,0001.  Long term surveillance is 
required in the majority of cases, involving regular cystoscopy. UCB results in 
significant mortality, with overall 5-year survival rates of 57% and 47% for 
men and women respectively when the disease presents as muscle-invasive1. 
As a result, UCB also represents a significant economic burden to healthcare 
systems as the most expensive malignancy to manage on a per patient basis 
from diagnosis to death2,3 Around 75-80% of patients present with non-
muscle-invasive disease (NMIBC), but recurrence and progression are 
significant issues, compelling current guidelines to recommend long-term 
surveillance4. There is therefore an urgent and unmet need to identify and 
validate accurate urinary biomarkers for the detection of disease recurrence in 
order to improve quality of life for NMIBC patients and reduce costs for 
healthcare providers, whilst maintaining or improving current outcomes. 
 
Characteristics of effective biomarkers include cancer-specific expression and 
release from tumors. One gene that has recently been shown to have these 
properties is the transcription factor Engrailed-2 (EN2), which is expressed in 
both breast cancer5 and prostate cancer6. The former study showed that EN2 
has oncogenic potential, as its forced expression in a non-malignant 
mammary epithelial line increased cell proliferation, survival and invasion5. 
We have recently shown that EN2 is also expressed in human prostate 
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cancer cell lines and patient tumors. Furthermore, full length EN2 protein can 
be released from prostatic cancer acini and ducts, and detected in the urine of 
prostate cancer patients, thus representing a potential diagnostic biomarker 
6,7
. In this study we show that EN2 is also expressed by bladder cancer 
tumors and is potentially a specific and sensitive biomarker for bladder 
cancer, even when the disease presents at early, non-invasive stages. 
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Materials and Methods 
 
Cell Lines 
Forty-three bladder tumor-derived cell lines, one line (HCV-29) derived from 
the non-malignant ureteric epithelium of a patient with bladder cancer, one 
telomerase immortalized NHU cell line (NHU-BTERT) and a pool of cultured 
primary normal human urothelial cells (NHU-Pool) isolated from 3 different 
donors were cultured for use in expression array experiments. Eight cell lines 
(LUCC1-8) were established in the Knowles laboratory. Cell lines were 
authenticated by short tandem repeat (STR) DNA typing using a Powerplex 
16 kit (Promega). Profiles were compared to publically available data (ATCC, 
DSMZ) or where no reference profile was available, were confirmed as 
unique.  
 
Growth conditions for the cell lines were as previously described6,8. The 
conditioned media used for EN2 detection was taken from cells grown to 90% 
confluence and then put in serum-free medium for 2 hours. 
 
Paraffin-Embedded Tissues and Immunohistochemistry 
Expression of EN2 in UCB and normal bladder tissue was investigated using 
3µm thick formalin fixed, paraffin embedded tissue array sections (BL2081, 
US Biomax, Rockville, MD, USA). Immunohistochemical analysis was 
performed using a polyclonal rabbit anti-EN2 antibody (Abcam, Cambridge, 
Cambridgeshire, UK #28731) diluted 1:100 and the ABC detection method 
with peroxidase block (DakoCytomation). Antigen retrieval was performed 
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using pH9.0 Tris/EDTA buffer (DakoCytomation) and heating in a microwave 
for 23 minutes. 
 
Immunostaining was assessed by a uropathologist and scored (independently 
by a second observer) on a 0-3 scale, with 0 representing no apparent 
staining and 3 very strong staining. The levels of expression in the tissue 
array cores were scored as no staining (score = 0), tumor with low level 
staining, cytoplasmic only (score = 1), tumor with moderate staining, 
cytoplasmic only (score = 2), and tumor with high staining both cytoplasmic 
and nuclear (score = 3). 
 
Gene expression profiling 
Total RNA for gene expression analysis was extracted using TRIZOL 
(Invitrogen, Paisley, UK), DNase-treated and cleaned up using a Qiagen 
RNeasy Mini Kit. Whole-genome expression profiling was performed using 
GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, 
CA, USA). 5 µg of total RNA from each cell line was labelled using the WT-
Ovation Pico Target Prep v1.0 system (NuGen Technologies Inc., San Carlos, 
CA, USA) and hybridised according to the array manufacturer’s instructions. 
The arrays were scanned and CEL files were imported into Partek Genomics 
Suite 6.5. Data were normalised and probe intensity measures were 
generated using the Robust Microarray Analysis (RMA)9. EN2 mRNA 
expression levels were represented as log10 (cell line intensity/NHU-Pool 
intensity). 
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cDNA Synthesis and RT-PCR 
RNA was extracted from the bladder cancer derived cell lines using the 
Qiagen RNeasy kit (Qiagen, USA). Three paired biopsy samples of human 
UCB and normal adjacent bladder were evaluated (one from each of three 
patients). Ethical approval for the evaluation of these samples was in place 
(10/H1101/7). All were confirmed histologically as bladder cancer or normal 
by a specialist uropathologist. cDNA synthesis and RT-PCR were performed 
as previously described6. 
 
EN2 protein detection  
EN2 detection by western blotting6 was carried out as previously described. 
For the ELISA, a monoclonal mouse anti-EN2 antibody, APS1, was generated 
(Antibody Production Services Ltd, Haywards Heath, Sussex, UK) using the 
synthetically produced EN2 C-terminal 100 amino acids (Biosynthesis Inc, 
Lewisville, Texas, USA). An APS1-Alkaline phosphatase conjugate was used 
to detect EN2 captured onto a 96-well plate (Nunc 436014, Rochester, New 
York, USA). 100 µl of the urine supernatant samples or a dilution of the EN2 
fragment in buffer was tested in duplicate. A standard curve was generated 
from dilution series to allow the concentration of EN2 in each sample to be 
measured. 
 
Patients and Controls  
Urine samples were collected prospectively for biomarker research between 
2006 and 2009 as part of the Bladder Cancer Prognosis Programme (BCPP, 
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ethics approval 06/MRE04/65)10. Previous biomarker discovery work on urine 
samples from BCCP has been published11. 
 
Statistical analysis 
The GraphPad prism package was used in statistical calculations. To test the 
significance of differences between mean EN2 concentrations in different 
patient groups we used an unpaired t-test with Welch’s correction. Receiver 
operator characteristics (ROC) curves were generated for the EN2 and the 
area under the curve tested for significance using an unpaired t-test against 
the hypothesis that the real area under the curve was 0·5 (i.e. no diagnostic 
value). For the qRT-PCR data we used the mean of 3 independent 
experiments and tested for significance using Student’s t-test with Welch’s 
correction.  
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Results 
 
EN2 expression in UCB 
The previous findings that EN2 is expressed by prostate6 and breast5 cancer 
cells led us to determine whether EN2 was also expressed in UCB. Evaluation 
of gene expression microarray data from a panel of UCB cell lines, including 
several derived from low grade and low stage UCB revealed that a majority of 
cell lines express higher levels of EN2 mRNA compared with normal 
urothelium controls (Fig 1a).  
 
A small panel of UCB derived cell lines (RT4, UMUC3, LUCC8, J82, EJ and 
RT112) and a telomerase immortalized NHU cell line as normal control (NHU-
BTERT) were subsequently cultured and the relative expression of EN2 in 
each was determined by  quantitative qRT-PCR (Fig 1b). This panel included 
cell lines representing high grade (J82, EJ) and low grade disease (RT112, 
LUCC8, RT4). After 24 hours of cell culture EN2 secretion was determined by 
ELISA. Moderate to high expression of EN2 was observed in RT4, UMUC3, 
EJ and RT112 lines. Low level expression was evident in the other lines 
including the NHU-BTERT line. However, only the 4 cell lines with the highest 
expression of EN2 secreted EN2 into supernatant: RT4, UMUC3, EJ and 
RT112. EN2 expression at the protein level was determined using a 
fluorescently labeled anti-EN2 antibody and high levels of expression were 
seen (Fig 1c). To confirm these in vitro findings, we demonstrated that EN2 
RNA expression was restricted to tumor in three tumor/normal paired samples 
from patients with UCB (p=0.0134), Fig 1d. 
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The expression of EN2 was subsequently studied in primary UCB tissue, 
including a high density tissue array comprising 180 tumor cores and 16 
normal bladder cores; EN2 protein was expressed by transitional cell 
carcinoma (TCC, Fig 2a), squamous cell carcinoma (SCC) (Fig. 2b) and 
adenocarcinoma of the bladder (Fig 2c). In TCC tumors, the pattern of EN2 
expression was cytoplasmic and nuclear, similar to that observed in prostatic 
adenocarcinoma. In adenocarcinoma and SCC expression was also 
cytoplasmic and nuclear but levels more heterogeneous within the same 
tumor deposit with areas of focal positivity. Scoring the tumor core 
immunostaining (Fig 2d-g) revealed no staining for normal bladder tissue but 
22-fold higher staining for all tumor types combined and 24-fold higher 
staining in TCC. SCC and adenocarcinoma had 17-fold and 6.4-fold higher 
staining than normal bladder, respectively (Fig 3). Higher grade tumors had 
progressively less EN2 expression than lower grade tumors - Grade 1 and 
Grade 2 tumors showed 2.3-fold and 1.9-fold more staining, respectively, than 
Grade 3 tumors (Fig 3). No differences in staining were apparent between 
tumors taken from male and female patients, nor was there any apparent 
relationship between staining and patient age (data not shown). 
 
EN2 protein is present in the urine of bladder cancer patients 
Given the expression of EN2 in UCB cell lines and tissue sections, secretion 
of EN2 by cell lines and our previous findings in prostate cancer, we assessed 
urinary EN2 levels in an independent cohort of patients with and without UCB 
(BCPP10). The characteristics of the patients included in the study are shown 
 11
in Table 1. For those patients with UCB there was an expected distribution of 
histological grades and stages, and a mean age of 72 years (range 29 to 94 
years, n=466); for the non-UCB (control) subjects the mean age was 71 years 
(range 34 to 88 years, n=52). 
 
Full length EN2 protein could be detected in the urine of cancer patients by 
western blotting (Fig 4a); to quantify the EN2 concentration in all of the 
samples, the urine was also analyzed by ELISA. The mean urinary EN2 
concentration in patients with UCB was 197ng/ml, whilst that for control 
subjects was 34ng/ml (Fig 4b). The majority of UCB patients were diagnosed 
with stage Ta or T1 tumors, and there was no significant difference between 
the mean urinary EN2 concentrations in these patients (171ng/ml and 
184ng/ml, respectively). The concentration of EN2 in the urine of patients with 
T2+ tumors was significantly higher than in those with Ta and T1 tumors, at 
261ng/ml. Higher grade tumors (Grades 2 and 3) were associated with higher 
mean urinary EN2 concentrations (192ng/ml for Grade 2 and 215ng/ml for 
Grade 3) than Grade 1 tumors (168ng/ml). 
 
Urinary EN2 concentrations are predictive for UCB 
The difference in urinary EN2 concentrations in patients with and without UCB 
indicated potential diagnostic value. A ROC analysis of these data gave an 
area under the curve of 0.844, which rises to 0.908 when comparing cancer 
patients to those individuals with entirely normal histology (Fig 4c). The ROC 
analysis indicated that the optimal urinary EN2 concentration threshold for 
cancer versus non-cancer was 55.5ng/ml in order to maximize the sensitivity 
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and specificity of the test. Using this cut-off gives a sensitivity for all UCB of 
82% with a specificity of 75%. The sensitivity for stages Ta, T1 and T2+ are 
71%, 76% and 94%, respectively (Table 1). Amongst the non-UCB patients, 
19% had >55.5ng/ml EN2 in their urine (4% for patients with entirely normal 
histology). 
. 
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Discussion 
 
In this study we have shown that EN2 is expressed by and secreted from 
UCB tumors.  These results highlight a potential role for EN2 in UCB 
pathogenesis (as seen in breast and prostate cancer5,6), and they also 
highlight the potential utility of EN2 as a urinary biomarker for UCB. 
Specifically, EN2 appears to be a more sensitive marker for NMIBC than 
existing markers. As EN2 expression was also detected in non-transitional cell 
tumors (squamous cell and adenocarcinoma), it will be important to establish 
whether EN2 is also secreted into urine by patients harboring these forms of 
bladder cancer. A variety of molecular changes are associated with squamous 
cell and adenocarcinoma histology and, combined with evidence of EN2 
expression/secretion in NMIBC and MIBC, it suggests a common regulatory 
defect. This is currently being investigated by our group. Squamous cell 
histology is common in countries where bladder cancer is associated with 
schistosomiasis13 and therefore EN2 may be useful in this high risk 
population, in contrast with other currently used markers which have been 
shown to be more specific for TCC histology. 
 
Current urinary biomarkers for UCB have important, significant limitations and 
none are reliable for post-treatment surveillance. In the evaluation of urinary 
EN2 as a diagnostic biomarker for UCB, EN2 was detected in the urine of 
most patients with NMIBC with an overall sensitivity of 82% and specificity of 
75%. In comparison, urine cytology has a high diagnostic specificity (78-
100%), but lacks robust sensitivity (12.2-84.6%), especially for low and 
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intermediate grade tumors14. The sensitivity of EN2 for stage Ta and T1 
tumors was 71% and 76%, respectively, and 94% for stage T2+ tumors. This 
compares favorably with existing markers. The sensitivity for tumor grades 1, 
2, and 3 was 69%, 78% and 87% respectively. This latter result apparently 
contradicts our IHC findings where EN2 staining was found to be relatively 
weaker in higher grade tumors. The most likely explanation for this would be 
that the structure of high grade tumors, and / or some aspect of their 
physiology allows for a more efficient release of EN2 protein into the urine. 
A number of other investigational urine markers have been described by Tilki 
et al in their recent review15,16, but currently the presence of Nuclear Matrix 
Protein 22 (NMP22) protein in urine represents the most sensitive protein-
based non-invasive test for early stage UCB . NMP22, a regulator of mitosis 
that escapes from bladder cancer cells undergoing apoptosis, can be 
detected in the urine and has been studied as a potential biomarker 15. It has 
a sensitivity of 46.7% and 48.2% for stages Ta and T1, respectively (a 
superior sensitivity to urine cytology), and a specificity of 90.3% in the 
absence of any urinary tract disease (reduced to 77.6% in inflammatory 
conditions)17. The fact that its sensitivity for stages Ta and T1 does not 
exceed 50% may reflect the primary mechanism for NMP22 release, thought 
to be the breakdown of cell membranes during apoptosis. Since earlier stage 
tumors undergo less apoptosis than more advanced tumors18, NMP22 release 
might also be expected to be less, limiting its diagnostic utility for NMIBC. 
Conversely, EN2 is actively secreted from viable cells19,20 and its presence in 
urine is likely to be associated with live tumor cells. Like NMP22, a number of 
other diagnostic tools also have a relatively high sensitivity for more advanced 
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stage cancers (stages T2+), but none of them currently allow for detection of 
more than 50% of earlier stage cancers. Upon validation, the first clinical 
application for urinary EN2 would be as a diagnostic test for patients either 
presenting for the first time (at a haematuria clinic), in order to increase 
diagnostic sensitivity and specificity, or for those under surveillance with an 
aim to reducing the number of screening cystoscopies. For both of these 
scenarios, the majority of patients will have NMIBC. EN2 may also be used as 
one of a panel of urinary markers, to provide a combined risk assessment21,22.  
 
We have found that EN2 is expressed in NMIBC and MIBC, and also in 
metastatic bladder cancer, by analysis of tissue microarrays (manuscript in 
preparation).  Our pilot study has shown that EN2 is expressed in, and 
secreted by, recurrent NMIBC and a prospective study of this specific group is 
on-going. The microarray data of cell lines confirmed EN2 expression in cells 
representing different stages and grades of disease.  This suggests that EN2 
expression / secretion may be an early event in bladder tumorigenesis and 
independent of the specific molecular dysregulation associated with either 
NMIBC or MIBC. The molecular basis of the observed de novo EN2 
expression and physiology of EN2 secretion by bladder cancer cells is 
currently being investigated.  
 
In previous studies, we demonstrated the potential utility of urinary EN2 for 
the diagnosis of prostate cancer6,7 which raises the question of how to 
interpret elevated urinary EN2 levels. This may be addressed in a number of 
ways. Firstly, the mean urinary concentration of EN2 in prostate cancer was 
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329ng/ml compared to 197ng/ml for UCB in this study, although the optimal 
cut-off values were similar (42.5ng/ml for prostate cancer and 55.5ng/ml for 
UCB6). Future prospective trials will be designed to include a further 
comparison of urinary EN2 levels between prostate cancer patients and UCB 
patients. Secondly, the clinical presentation and diagnostic pathways are very 
different for UCB and prostate cancer. Bladder cancer usually presents with 
hematuria, whilst prostate cancer is diagnosed when investigating lower 
urinary tract symptoms, a strong family history of prostate cancer, a PSA test 
(due to symptoms or a scheduled general male health screen) or an abnormal 
digital rectal examination. Prostate cancer is only rarely associated with 
haematuria. Whilst the symptoms associated with both bladder and prostate 
cancer may also be attributable to non-cancer causes, their presence in 
conjunction with a positive EN2 test would strongly indicate the presence of 
bladder or prostate cancer and the need for further investigation.  The 
adoption of EN2 as a new standard diagnostic biomarker will require multi-
center prospective evaluation, either as a single marker or in conjunction with 
existing tests. Although it has potential in screening, surveillance and early 
detection, initial evaluation would most likely be undertaken in the haematuria 
clinic setting as a diagnostic test. This would establish its negative and 
positive predictive values which are directly related to sensitivity and 
specificity, and the prevalence of the disease in a defined population. 
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Figure legends 
 
Figure 1. EN2 expression in bladder cancer derived cell lines. (a) Relative 
EN2 expression measured by micro-array across a range of normal bladder 
and bladder cancer derived cell lines. (b) Upper panel – qRT-PCR analysis of 
EN2 transcripts in the bladder cancer derived cell lines EJ, UMUC3, RT4, 
LUCC8, J82, and RT112, together with the transformed, normal bladder cell 
line B TERT. Expression is shown as a ratio with the house keeping gene 
Beta-actin (x1000). Error bars show the SEM (n=3).  Lower panel - EN2 
secretion by the same cell lines as measured by an ELISA. (c) Fluorescent 
micrograph of EJ cells stained with a FITC-labeled anti-EN2 antibody. EN2 
staining is shown in green. Cell nuclei are stained blue (DAPI). Scale bar: 
5µm. (d) qRT-PCR analysis of EN2 expression in bladder tumors and normal 
adjacent tissue (NAT). Expression is shown as a ratio with the house keeping 
gene Beta-actin. Error bars show the SEM (n=3). 
 
Figure 2. EN2 staining of bladder cancer sections with an anti-EN2 antibody 
(brown). Expression by immunohistochemistry in transitional (a) x10 
magnification, squamous (b) x20 magnification, and adenocarcinoma 
histology (c) x 20 magnification. Expression pattern in transitional cell 
carcinoma was uniform cytoplasmic staining with some nuclear positivity. The 
expression in squamous cell and adenocarcinoma variants was much more 
heterogeneous within tumors with focal positivity in cytoplasm. Scoring of 
tissue expression of EN2 in tissue array: (d) no staining (score= 0), (e) tumor 
with low level staining, cytoplasmic only (score = 1), (f) tumor with moderate 
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staining, cytoplasmic only (score =2), (g) tumor with high staining both 
cytoplasmic and nuclear (score =3). Scale bar: 10µm. 
 
Figure 3. Scoring of EN2 staining in bladder tumors. EN2 staining was scored 
from 0 to 4, whereby ‘0’ is no staining and ‘4’ is very strong staining tumor. 
The proportion of each tumor type or tumor grade having a given score (s) is 
shown. ‘Normal’ – normal bladder tissue (n=16), ‘All ca’ – all cancer types 
(n=180), ‘TCC’ – transitional cell carcinoma (n=149), ‘SCC’ – squamous cell 
carcinoma (n=16), ‘Adenoca’ – adenocarcinoma (n=15), tumor‘G1’ - Grade 1 
(n=57), ‘G2’ - Grade 2 (n=65), and ‘G3’ - Grade 3 (n=31). It was not possible 
to grade all tissue samples on the array due to quality of staining. 
 
Figure 4. EN2 in urine. (a) Western blot of urine from bladder cancer patients 
(‘C’) or a non-cancer patient (‘N’). (b) Mean urinary EN2 concentrations for 
bladder cancer patients and non-cancer patients in Birmingham. ‘All Ca’ – all 
cancer stages / grades combined. ‘Ta’ –stage Ta, ‘T1’ –stage T1, ‘T2’ – stage 
T2, ‘G1’ – Grade G1, ‘G2’ – Grade G2, ‘G3’ – Grade 3, ‘All non-Ca’ – all non-
cancer patients combined. Error bars show the SEM. (c) ROC analysis of all 
cancer urine samples v either all non-cancer urines (black) or only urine 
samples from patients with entirely normal bladder tissue (and thus no cystitis, 
grey). 
 
Table 1. Summary of data from Birmingham patients. ‘All Ca’ – all cancer 
stages / grades combined. ‘Ta’ –stage Ta, ‘T1’ –stage T1, ‘T2’ – stage T2, 
‘G1’ – Grade G1, ‘G2’ – Grade G2, ‘G3’ – Grade 3, ‘Non Ca’ – all non-cancer 
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patients combined. ‘ROC’ – area under the ROC curve generated from 
comparing the group to the non-cancer patients. ‘%EN2+’ -  proportion of 
samples positive for EN2 (cut off = 55.75ng/ml). ‘%spec’ - % specificity.  
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Table 1 Summary of data from the BCPP patients.  
 
Group n Mean 
age 
(range) 
Mean 
[EN2] 
ng/ml 
ROC 
(95% CI) 
% EN2+  % spec 
All Ca 466 72 
(29-94) 
197 0.844 
(0.797-
0.890) 
82 
 
75 
 
Ta 251 71 
(29-94) 
171 0.811 
(0.756-
0.867) 
71 
 
75 
 
T1 113 73 
(47-93) 
184 0.828 
(0.765 to 
0.890) 
76 
 
75 
 
T2 102 75 
(43-93) 
261 0.927 
(0.884 to 
0.970) 
94 
 
75 
 
G1 111 70 
(36-92) 
168 0.793 
(0.725 to 
0.861) 
69 
 
75 
 
G2 140 70 
(29-94) 
192 0.826 
(0.766 to 
0.886) 
78 
 
75 
 
G3 215 75 
(43-93) 
215 0.881 
(0.834 to 
87 
 
75 
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0.927) 
All Non 
Ca 
55 71 
(34-88) 
35 - 
 
 
19 
 
- 
 
Cystitis 27 73 
(45-87) 
53 - 33 - 
Normal 28 69 
(34-88) 
15 - 4 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
